Inovio Pharmaceuticals, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark Bagarazzi. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark Bagarazzi has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:INO / Inovio Pharmaceuticals, Inc. Chief Medical Officer 55,133
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark Bagarazzi. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases INO / Inovio Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INO / Inovio Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2013-04-16 INO Bagarazzi Mark 60,000 0.5590 5,000 6.7080 33,540 337 733.44 3,633,660 10,833.81

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INO / Inovio Pharmaceuticals, Inc. Insider Trades
Insider Sales INO / Inovio Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INO / Inovio Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INO / Inovio Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark Bagarazzi as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2019-03-07 2019-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -27,567 55,133 -33.33
2019-03-07 2019-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -8,408 100,672 -7.71 3.61 -30,353 363,426
2019-03-07 2019-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 27,567 109,080 33.82
2018-03-13 2018-03-10 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -20,434 40,866 -33.33
2018-03-13 2018-03-10 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -5,653 81,513 -6.49 4.51 -25,495 367,624
2018-03-13 2018-03-10 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 20,434 87,166 30.62
2018-03-13 2018-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -25,000 25,000 -50.00
2018-03-13 2018-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -6,896 66,732 -9.37 4.51 -31,101 300,961
2018-03-13 2018-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 25,000 73,628 51.41
2018-03-07 2018-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
A - Award 82,700 82,700
2018-03-07 2018-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Option
A - Award 126,500 126,500
2018-03-07 2018-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -8,333 0 -100.00
2018-03-07 2018-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -2,815 48,628 -5.47 4.29 -12,076 208,614
2018-03-07 2018-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 8,333 51,443 19.33
2017-03-13 2017-03-10 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
A - Award 61,300 61,300
2017-03-13 2017-03-10 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Options
A - Award 100,000 100,000 6.68 668,000 668,000
2017-03-13 2017-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -25,000 50,000 -33.33
2017-03-13 2017-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -7,648 43,110 -15.07 6.61 -50,553 284,957
2017-03-13 2017-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 25,000 50,758 97.06
2017-03-07 2017-03-06 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -3,067 25,758 -10.64 6.95 -21,316 179,018
2017-03-07 2017-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -8,333 8,333 -50.00
2017-03-07 2017-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 8,333 28,825 40.66
2016-03-11 2016-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
A - Award 75,000 75,000
2016-03-11 2016-03-09 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Option
A - Award 67,500 67,500 7.02 473,850 473,850
2016-03-08 2016-03-07 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
F - Taxes -2,842 20,492 -12.18 7.48 -21,258 153,280
2016-03-08 2016-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
M - Exercise -8,334 16,666 -33.34
2016-03-08 2016-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
M - Exercise 8,334 23,334 55.56
2015-03-09 2015-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Restricted Stock Unit
A - Award 25,000 25,000
2015-03-09 2015-03-05 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Options
A - Award 60,000 60,000 7.56 453,600 453,600
2014-05-23 2014-05-22 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Option
A - Award 155,000 155,000 2.20 341,000 341,000
2014-03-27 2014-03-26 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Options
A - Award 150,000 150,000 3.23 484,500 484,500
2013-04-16 2013-04-16 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock
P - Purchase 60,000 60,000 0.56 33,540 33,540
2013-03-18 2013-03-14 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Options
A - Award 180,000 180,000 0.54 97,200 97,200
2012-02-27 2012-02-23 4 INO INOVIO PHARMACEUTICALS, INC.
Common Stock Options
A - Award 175,000 175,000 0.60 105,000 105,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)